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Plasma cells (PCs) are responsible for the production of protective antibodies against
infectious agents but they also produce pathogenic antibodies in autoimmune diseases,
such as systemic lupus erythematosus (SLE). Traditionally, high affinity IgG autoantibodies are thought to arise through germinal center (GC) responses. However, class
switching and somatic hypermutation can occur in extrafollicular (EF) locations, and this
pathway has also been implicated in SLE. The pathway from which PCs originate may
determine several characteristics, such as PC lifespan and sensitivity to therapeutics.
Although both GC and EF responses have been implicated in SLE, we hypothesize that
one of these pathways dominates in each individual patient and genetic risk factors
may drive this predominance. While it will be important to distinguish polymorphisms
that contribute to a GC-driven or EF B cell response to develop targeted treatments,
the challenge will be not only to identify the differentiation pathway but the molecular
mechanisms involved. In B cells, this task is complicated by the cross-talk between
the B cell receptor, toll-like receptors (TLR), and cytokine signaling molecules, which
contribute to both GC and EF responses. While risk variants that affect the function of
dendritic cells and T follicular helper cells are likely to primarily influence GC responses,
it will be important to discover whether some risk variants in the interferon and TLR
pathways preferentially influence EF responses. Identifying the pathways of autoreactive
PC differentiation in SLE may help us to understand patient heterogeneity and thereby
guide precision therapy.
Keywords: systemic lupus erythematosus, autoantibodies, B cells, plasma cells, tolerance

INTRODUCTION
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the
production of pathogenic autoantibodies that target a variety of nuclear self-antigens, some of
which cross-react with tissue antigens. These autoantibodies cause tissue inflammation and lead
to organ damage in the kidneys, skin, and more. Presence of IgG ANA is a diagnostic feature
Abbreviations: AID, activation-induced cytidine deaminase; BCR, B cell receptor; BM, bone marrow; CSR, class switch
recombination; DC, dendritic cell; EF, extrafollicular; FDC, follicular dendritic cell; FO, follicular; GC, germinal center; ICOS,
inducible T-cell costimulator; IFN, interferon; MHC, major histocompatibility complex; MZ, marginal zone; PB, plasmablast;
PBMC, peripheral blood mononuclear cell; PC, plasma cell; pDC, plasmacytoid dendritic cell; SHM, somatic hypermutation;
SLE, systemic lupus erythematosus; Tfh, T follicular helper; TLR, Toll-like receptor.
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for SLE and other systemic autoimmune diseases, and these
antibodies have an important role in disease pathogenesis (1, 2).
In contrast, IgM ANA are considered to be protective against
autoimmunity. They can be present in healthy individuals and
assist in the non-inflammatory clearance of cellular debris and
inhibit responses induced by IgG ANA (3–5). Other isotypes
include IgA and IgE, but the pathogenicity of these isotypes has
been less well studied.
Antibodies are secreted by plasma cells (PCs), which arise as a
terminal differentiation step from B cells. Most of our knowledge
of immune tolerance to nuclear antigens, and the break of tolerance in SLE patients, is derived from studies with B cell receptor
(BCR)-transgenic mice and single cell studies in humans, where
self-reactivity is usually censored in developing B cells prior to
their achieving immunocompetence (6, 7). Autoreactive cells that
escape these mechanisms often become anergic (8–10), a process
that mitigates against these cells giving rise to high affinity IgG
autoantibody-producing PCs.
Plasma cells can arise through two pathways: through activation of B cells and direct differentiation in extrafollicular (EF) foci
or through a germinal center (GC) response. Although traditionally pathogenic high affinity autoantibodies have been associated
with the GC response, recent insights have implicated the EF
pathway in SLE as well. We hypothesize that both pathways can
contribute to production of SLE autoantibodies. Understanding
the regulation of each pathway and how genetic risk alleles may
preferentially target one or the other of these pathways will be the
focus of this review.
Different subtypes of PCs have been described, including
plasmablasts (PB), pre-PC, early PC, short-lived PC, and longlived PC. These terms are sometimes used interchangeably
or not clearly defined. The confusion in part derives from the
original paradigm that the EF pathway only results in short-lived
proliferating PBs, whereas the GC pathway was thought to result
only in long-lived quiescent PCs (11). However, lifespan and
proliferation can operate independently from each other, such
that there are short-lived PCs which are not proliferating, and
long-lived PCs from GC origin can proliferate prior to becoming
quiescent (12–14). In addition, PC differentiation is a continuum
where expression of canonical B cell markers [B220, CD19, major
histocompatibility complex (MHC) class II] is gradually lost and
PC markers (such as Blimp-1, CD138, secreted Ig) are gradually upregulated (14). It is therefore difficult to define specific
PC subsets based on the expression of these markers. Here, we
define PCs as antibody secreting cells and we will only mention
specific PC subsets if these have been clearly verified. Definitions
used in this review are PBs, if proliferation has been verified;
short-lived plasma cells, if a short lifespan of <7 days has been
shown; or long-lived PC, if a long lifespan of >28 days has been
demonstrated.

of antigen. Antigens can activate B cells in a T-independent or
T-dependent manner. T-independent responses do not require
cognate T cell help. T-independent activation therefore leads
to plasma cell differentiation in the absence of GCs. There
are two types of T-independent antigens that can induce
activation of B cells; TI-1 antigens can activate B cells through
coengagement of Toll-like receptors (TLR), such as LPS or
other bacterial polysaccharides, whereas TI-2 antigens lead to
extensive crosslinking of the BCR, such as polymeric protein
antigens or repeated structural motifs (15). In TI-2 responses,
competition for antigen enhances the activation and expansion
of high-affinity cells, while antigen affinity is less important in
TI-1 responses (16).
Although TI-1 and TI-2 antigens have been considered to
induce T cell-independent responses, it is now clear that this
distinction is not absolute: TI-2 and possibly TI-1 antigens
can induce a transient GC (17), and the TI-2 serum antibody
responses, in particular IgG, can still be T cell-dependent, even if
the antigen cannot directly trigger T cells through MHC class II
(18). It has therefore been proposed that the characteristics of the
antigen is not the leading determinant of the response, but rather
the B cell subset and the ancillary cell types involved determine
the nature of the response (19).
In addition to the strength of the initial stimulus through the
BCR and cognate and non-cognate T cell interactions, B cell
activation is also modified by the presence of other potent stimuli.
Pattern recognition receptors, such as TLRs, interact with damageassociated molecular patterns or highly conserved microbial
structures present in bacteria or virus. Included among these
are both dsDNA (CpG enriched) and RNA. Many TLRs signal
through MyD88, and MyD88-deficient mice have diminished antibody responses, both early and late after immunization (20–23).
Simultaneous engagement of the BCR and TLRs has a synergistic
effect on signaling and subsequent B cell activation (24).
Cytokines, such as type I interferon (IFN), IL-6, and BAFF, can
activate B cells and enhance both T-independent and T-dependent
activation (25–27). BAFF has three recognized receptors, and
one of them, TACI, signals through MyD88 (28), the same adaptor used by TLR7 and TLR9. Antigen-presenting cells, such as
dendritic cell (DC) and macrophages, induce CD40-independent
PC differentiation through secretion of cytokines such as BAFF
and APRIL (26).
Two processes that alter the antibody response are somatic
hypermutation (SHM) and class switch recombination (CSR),
both of which are mediated by the enzyme activation-induced
cytidine deaminase (AID) (29). These processes can change
antigen recognition by the BCR (SHM) or change the isotype that
is expressed (CSR), and are usually associated with GC responses
(discussed below). Although T-independent responses are usually
associated with the IgM isotype, CSR can occur in certain infections and does not require cognate T–B interactions (30). CSR can
be driven by MyD88 signaling or cytokines such as BAFF, APRIL,
IFN-gamma, and IL-21 (20, 23, 31, 32).

T-INDEPENDENT B CELL ACTIVATION
AND PC DIFFERENTIATION

B-1 Cells

The B cell lineage consists of several subsets and cells diverge
early in development. Each of these naive cell subsets can give
rise to PCs, but they each preferentially respond to specific types
Frontiers in Immunology | www.frontiersin.org

B-1 cells represent a distinct population of B cells that arises
during fetal development (33, 34). They are mainly found in the
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FO B Cells

peritoneal and pleural cavities of mice and are rare in lymphoid
organs and blood (Figure 1) (35). B-1 cells generally express
germline-encoded, polyreactive IgM and IgA antibodies with
limited V-gene segment usage, and are activated by T-independent
antigens, such as LPS (TI-1) or multivalent antigens (TI-2)
(36–38). In mice, B-1 cells can be further divided into B-1a
and B-1b according to the expression of CD5 (CD5+ or
CD5−, respectively). B-1a cells have been proposed as a major
source of natural autoantibodies (37–40). These low-affinity
polyreactive antibodies can be secreted spontaneously and
are important in the clearance of apoptotic debris. They also
contribute to protection against pathogens such as Streptococcus
pneumoniae and influenza (41, 42). B-1b cells respond primarily
to T-independent antigens (TI-1 and TI-2) and generate IgM
memory cells, which contribute to protection against reinfection with Borrelia hermsii, S. pneumoniae, and Salmonella (19,
41, 43–45).
B-1 cells are poor at forming GCs (46); however, class-switched,
somatically mutated B-1 antibodies showing evidence of antigen selection have been isolated from humans (47). Although
elevated numbers of B-1 cells are present in some lupus-prone
mouse strains (36, 48), there is not a clear association with SLE
(49, 50).

Follicular B cells are migratory cells that move between
lymph nodes, splenic follicles and the circulation until they
interact with antigen. While MZ B cells are specialized in the
response to T-independent antigen, they can also transport
these antigens to the follicles and transfer such antigens to
FO B cells (56, 57). However, compared to MZ B cells which
become blasts within 24 h of mitogen activation, FO B cells
do not show blast formation in response to mitogen, due to
their requirement for cognate T cell help, and therefore the
contribution of FO B cells in T-independent responses is probably limited (51).

T-CELL-DEPENDENT ACTIVATION
OF B CELLS
Although there are models where T-independent responses
can contribute to lupus in mice (58, 59), the majority of
studies in lupus-prone mice and SLE patients suggest that
T-dependent responses are the main driver of the disease.
Therefore, we will focus on T cell-dependent responses for the
remainder of this review. Here, we will first discuss the initial
activation of B cells in a T-dependent response, including
the cell fate decisions into either the EF or the GC pathway,
followed by a discussion of the PC differentiation pathways
after they diverge.
T-dependent responses are thought to be dominated by FO
B cells, although MZ B cells can migrate to the T–B border, activate T cells, and enter a GC (60–63). Although it is unclear how
much they contribute to class-switched GC-derived antibody
responses, MZ B cells can certainly contribute to T-dependent
EF responses (Figure 2) (64, 65). MZ B cells can also capture and
deliver blood borne antigens to the follicles, thereby enhancing
T-dependent FO responses (66). This indicates that although
MZ B cells do not require cognate T cell interactions for their
differentiation into PCs, they can still participate in T-dependent
responses (Figure 2).

Marginal Zone (MZ) B Cells

Marginal zone and follicular (FO) B cells differentiate from
transitional B cells and both can participate in T-dependent
and T-independent immune responses. MZ B cells are located
in the MZ of the spleen, where they can serve as a first line of
defense to T-independent and blood-borne antigens, such as
lipopolysaccharide from bacteria (51). They are characterized by
high responsiveness to TLR activation, as well as a preactivated
state with high expression of complement receptors and costimulatory molecules. Due to these characteristics, they are known
for their ability to quickly differentiate into PCs in response
to T-independent antigens (51–53). MZ B cells do not require
cognate T cell help, as soluble factors such as cytokines and
costimulation derived from DCs, neutrophils, iNKT cells, and
T cells, can also lead to their activation, CSR, and differentiation
into PCs (28, 31, 54, 55).

Figure 1 | B cell subsets in T-independent plasma cell development. B-1
cells in the peritoneal and pleural cavities can produce antibodies of the IgM
and IgA isotype, either spontaneously (B-1a) or in response to T-independent
antigens (B-1a and B-1b). Marginal zone B cells produce mostly IgM in
response to T-independent antigens.

Frontiers in Immunology | www.frontiersin.org

Figure 2 | B cell subsets in T-dependent plasma cell (PC) development.
Both marginal zone B cells and follicular (FO) B cells can contribute to the
extrafollicular (EF) PC response, whereas the germinal center (GC) response
and subsequent PC differentiation is predominantly driven by FO B cells.
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Recirculating FO B cells are activated by antigen in peripheral tissues or in lymphoid tissue where they encounter soluble
antigen or antigen arrayed on follicular dendritic cells (FDCs).
Activated B cells upregulate chemotactic factors (CCR7, EBI2)
that favor their migration to the B–T border in the lymph nodes
or spleen (67, 68). At the same time, CD4+ T cells are activated
by DCs in the T cell zone, and these activated T cells will also
migrate to the B–T cell border. The differentiation of Th cells
[Th1, Th2, Th17, T follicular helper cells (Tfh)] is determined by
T cell–DC interactions and is driven by the engagement of pattern recognition receptors by pathogens- or damage-associated
molecules (69). At the T–B border, cognate interactions between
antigen-specific B and T cells drives initial proliferation, and some
B cells will undergo immunoglobulin CSR under the influence of
T cell-derived cytokines (60, 70–73).
After activation, B cells can diverge into EF PCs and GC
B cells. While it is well known which transcription factors drive
the differentiation into GC B cells versus EF PCs, whether there
is direct competition between EF and GC differentiation has not
been fully demonstrated. Since B cells can proliferate at the T–B
border prior to making cell-fate decisions, it is possible that the
distinction between cells with the same high affinity that enter an
EF or a GC pathway is partly stochastic and that the same B cell
clone can be found in both pathways (74, 75).
Under non-competitive conditions, low-, medium-, or highaffinity B cells can all seed a GC, whereas the low-affinity cells are
unable to generate an EF antibody response (76), due to failure to
expand low-affinity EF PCs rather than a lack of initiation of PC
differentiation (75). In contrast, under competitive conditions,
low-affinity cells compete with high affinity cells and are unable
to expand or enter a GC response (77). The advantage of high
affinity B cells in each response can be at least partly explained
by the degree of T cell help that is received, as high affinity B cells
stimulated with antigen express higher amounts of MHC class II
in the membrane, and are able to present more peptide to T cells,
establishing a more effective immunological synapse (77), which
can affect both EF and GC responses.
Although TLR activation during T-independent responses
clearly increases the magnitude of the EF response, TLR ligation
in T-dependent responses can enhance both the GC response
and the EF response (22), in a B cell-extrinsic or -intrinsic
manner (78).

lead to heavy chain CSR as well as initiation of PC differentiation
(Figure 4).
Under the influence of CXCR4, EF PCs migrate to the red
pulp, where they can further proliferate and differentiate in EF
foci. Proliferation is driven by BCR signaling, as cells with high
affinity BCRs have increased proliferation and decreased apoptosis compared to cells with low affinity BCRs (75). Cofactors,
such as CD19 and other molecules that enhance BCR signaling,
can enhance EF proliferation. Lyn, an inhibitory molecule in the
BCR signaling pathway, can diminish proliferation while in fact
driving terminal PC differentiation (16). After the proliferative
stage, PBs will differentiate further into PCs, characterized by
higher expression of Blimp-1, further loss of MHC class II and
costimulatory molecules. However, as discussed below, many
EF PBs are short-lived and die prior to full differentiation into
PCs (75). Some, however, complete their PC differentiation, after
which they can survive in specialized niches in the spleen or bone
marrow (BM) (12, 14).
Recent evidence suggests that several characteristics previously attributed to GC responses can also occur in EF responses.
This includes the formation of memory B cells, CSR, SHM, and
induction of long-lived PCs (discussed below). Whereas the
previous understanding was that memory B cells are generated
only in the GC, memory cells initially appear in blood before
GC formation (81), and Bcl-6-deficient mice, which are unable
to form GCs, generate memory cells (82). Most of these are nonmutated and IgM + memory cells, suggesting an EF origin at
least for some memory cells. Although CSR and a low degree
of SHM occur during early B–T interactions at the T–B border,
continued AID expression and affinity maturation in EF sites has
been observed (83).

GC Responses

Germinal centers are areas of T-dependent B cell development
in spleen, tonsils, lymph nodes, and Peyers’ patches. FDCs are
important for normal splenic architecture and B cell development, as well as for maintaining the structure and function of the
GC (84). Importantly, they capture antigen in immune complexes
and retain the antigen in native form. Antigens are presented
by FDCs on the cell surface (85). Several sequential events are
involved in the formation of the GC. At the T–B border, B cell and
T cell encounter with antigen stimulates formation of a GC (86),
and migration from the T–B border into the follicle is mediated
by CXCR5 (87). B cells receiving more T-help are more prone to
differentiate into GC B cells (88, 89), and T cells differentiate into
Tfh under the influence of B cell costimulatory molecules, including OX40L and CD80, which are essential for the maturation of
Tfh cells (90, 91). The transcription factor Bcl-6 is required for
the development of both GC B cells and Tfh cells (92). Tfh cells
are specialized T helper cells that are involved in the selection and
survival of B cells in the GC. The canonical costimulatory signal
involved in the B–T cell interaction in the GC is CD40–CD40L
(93, 94), but other signals such as ICOS–ICOSL, and IL-21 produced by Tfh cells are also required (95, 96).
The structure of the GC, with a light zone and a dark zone,
aligns with the processes of SHM, affinity maturation, and
selection (Figure 5). B cells in the light zone are referred to as

PC DIFFERENTIATION
PC Differentiation in EF Responses

As EF PCs can provide an initial wave of secreted antibodies
during the first week of an infection, these cells are an important
part of the initial antibody response against pathogens (11).
During expansion at the T–B border, those cells destined to
become EF PCs will upregulate Blimp-1, CD138, and CXCR4
(79). Differentiation of EF PCs is driven by T–B interactions with
a specific subset of Th cells that resembles Tfh cells but is located
in EF areas. These Th cells are dependent on Bcl-6 and Stat3, and
their interaction with B cells is mediated through CD40-CD40L
and inducible T-cell costimulator (ICOS)–ICOSL interactions as
well as cytokines, such as IL-21 (75, 79, 80). These interactions
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centrocytes. They interact with FDCs through antigen and
with Tfh cells through MHC–peptide interactions (97). Those
B cells which make stronger interactions with Tfh cells, due to
an increased T cell receptor peptide–MHC interaction, are positively selected and enter the dark zone where their proliferation
is greater (98, 99). As more antigen is added, the population of
B cells with BCRs that bind antigen sufficiently to induce positive
selection increases (99). Positive selection in the light zone is
important as it leads to GC B cells with the greatest affinity for
antigen. Interactions between Tfh cells, antigen, and B cells in
the light zone determine the extent of proliferation in the dark
zone (99). Fewer cells move from the light zone to the dark zone
than from the dark zone to the light zone indicating that selection
occurs in the light zone (99, 100).
The dark zone is the location where the most active proliferation
of GC B cells takes place, as all GC B cells that are in G2 or M phase
are in the dark zone; however, S phase cells are present in both
the light zone and dark zone (100). Proliferation can occur under
the influence of mTORC1 kinase, which activates the metabolic
program that permits proliferation of B cells in the dark zone (98).
After positive selection in the light zone and while undergoing
proliferation in the dark zone, SHM occurs to effect a process called
affinity maturation. During this process, point mutations occur
in the BCR which affect its affinity for antigen. When the B cell
returns to the light zone, the B cells that have undergone mutations
to enhance affinity for the antigen are preferentially selected (101).
A stronger interaction with Tfh cells in the light zone allows the
B cell to undergo more rounds of proliferation in the dark zone.
Therefore, each time the cell divides and more mutations are
acquired, more affinity maturation can occur for B cells that were
most positively selected for in the light zone (99).
Negative selection also occurs in the GC. B cells with weak
affinity for antigens in the GC, or autoreactive B cells recognizing
ubiquitously expressed self-antigens are eliminated (102, 103).
Proposed mechanisms for the negative selection of these B cells
are Fas-mediated apoptosis of cells that fail to bind antigen, failure to receive continuing T cell help, or the activity of T follicular
regulatory cells (Tfr) (102). A recent study, however, suggests that
negative selection primarily occurs in cells with an unproductive
BCR as a consequence of SHM rather than in cells with lower
affinity (104).

Certain cytokines favor the development of PCs. Among
them, IL-21 is the most potent inducer of PC differentiation from
memory and naive B cells (110, 111). This cytokine is produced
by Tfh cells in the GC and activates the JAK1/3 STAT3 pathway.
IL-21-deficient mice are unable to generate fully functional GCs.
Without IL-21 or Tfh cells, PC formation is disrupted, affinity
maturation does not occur, and the population of memory B cells
is expanded (91, 96, 110).
Toll-like receptor ligands also enhance GC responses through
both DCs and B cells (21, 78, 112). Whereas soluble TLR ligands
can enhance GC responses through an effect on DCs, an antigen
that can trigger both endosomal TLRs and BCRs can enhance
the IgG antibody response in a B cell-intrinsic manner (21). This
probably reflects the requirement for BCR-mediated uptake of
ligands for endosomal TLRs in this process, and explains why
some studies reported no effect of TLR signaling on GC responses
induced with LPS (113, 114). B cell-intrinsic MyD88 signaling
specifically enhances the formation of GC B cells, affinity maturation, and CSR in response to the TLR-9 ligand CpG coupled to
the hapten NP, without affecting the number of PCs. In contrast,
MyD88 signaling in DCs contributes to PC differentiation without affecting affinity maturation (78).
Different transcription factors are involved in the differentiation
of PCs and memory B cells. Bach2 is reported to be important
for selection of GC B cells into memory B cells; in the light zone,
B cells with lower affinity for antigen have higher expression of
Bach2, probably due to a lower degree of T cell help in those cells
(105, 115). In addition to Bach2, ABF-1 leads to memory B cell
differentiation and prevents PC differentiation (116). The transcription factors Blimp-1, XBP-1, and IRF4 are all involved in PC
differentiation (117–119). Blimp-1 leads to decreased expression of
genes involved in B cell signaling pathways including Pax5, which
in turn leads to increased expression of Blimp-1 and XBP-1. This
feed-forward mechanism is needed for PC differentiation (120,
121). Whereas Blimp-1 is required for PC differentiation, XBP-1 is
more specifically needed for the unfolded protein response that is
required for the production of high amounts of immunoglobulin
in PCs (122).
It has been recently reported that PC differentiation is initiated
in light zone B cells after which they migrate to the dark zone
to further differentiate (108). Together with simulation data,
this suggests that PCs exit the GC through the dark zone (123).
Similar to the EF response, GC-derived PCs are characterized
by a proliferative PB stage. Proliferating PBs have been reported
in the dark zone of the GC, as well as the T–B border directly
adjacent to the GC (123, 124), and their proliferation decreases
as they migrate further from the GC, and is completely lost as
they reach the medulla of the lymph node or the splenic red pulp
(124). This suggests that proliferation of GC-derived PBs occurs
during their transit out of the GC, at distinct locations from EF
PBs, which proliferate in EF foci mainly in the red pulp of the
spleen or the medulla of the LN. Some GC-derived PCs migrate
to the red pulp in the spleen or the medullary cords in the lymph
nodes, and others migrate through the blood to the BM (14, 81).
Their exit out of the secondary lymphoid organs occurs prior to
completion of their differentiation, as circulating PBs that arise in

PC Differentiation in the GC

Both memory B cells and PCs arise from the GC, and many
studies have examined the factors that determine if a given B cell
will become a memory B cell or a PC. High affinity GC B cells
become PCs, while lower affinity GC B cells become memory
B cells (105–107). The initiation of PC differentiation in the light
zone requires strong affinity for antigen; further differentiation in
the dark zone requires help from Tfh cells (108). Light zone B cells
become memory B cells early in the GC reaction, while PCs are
formed later (105, 109). Preventing apoptosis in the GC allows
for lower affinity B cells to become memory B cells but does not
change the development of PCs, further suggesting that selection
of B cells into the PC population is dependent on high affinity for
antigen (106).
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GC responses in humans show signs of recent proliferation such
as expression of Ki67 (14, 125).

the time window for tolerance checkpoints. Therefore, it is likely
that autoreactive B cells can be activated during EF responses,
either through direct activation by self-antigen in an inflammatory milieu, cross-reactivity with foreign antigen, or through
TLR ligands or cytokines (148). However, even if autoreactive
PCs are generated in EF responses, they are mostly short-lived
limiting the inflammation and tissue damage that is induced by
autoantibodies. Therefore, the transient nature of the EF response
may itself be a tolerance mechanism.
In addition to the short-lived nature of the response, tolerance in EF responses can be maintained through the balance
between IgM and other (more pathogenic) isotypes. As most EF
PBs secrete IgM, even though some CSR can occur, the balance
between IgG and IgM that is generated in EF responses may result
in prevention of autoimmunity, through downregulating myeloid
cell activation in a LAIR-1 dependent fashion and minimizing
local inflammation (3, 5, 149). In addition, sialylation of IgG
antibodies, which occurs in T-independent responses can also
contribute to tolerance, as these antibodies have lower pathogenicity, at least in the context of rheumatoid arthritis [(150),
p. 296; (151), p. 429].
T cell help during initial activation might play a role in tolerance in EF foci, where class-switched EF responses can occur
through cytokines secreted by bystander T cells or non-T cells.
Since there is no requirement for cognate T cell help, the
T cell repertoire is unlikely to restrict autoreactivity in the EF
response.

PC Survival

Two studies in the late 1990s showed the existence of long-lived PCs,
disputing previous thinking that PCs were short-lived (126, 127).
A more recent study showed that 10 years after vaccination, longlived PCs were still present in the BM, despite memory B cell
depletion (128). Another study shows the survival of these long
lived PCs despite CD19 directed CAR T cell therapy (129). These
PCs have become a challenge in treatment of SLE, as they are
often not eliminated by traditional therapies (130, 131). Although
most evidence suggests that selection of PCs into the long-lived
PC pool is dependent on extrinsic factors (132, 133), there is some
evidence that B cell-intrinsic factors are also involved (134, 135).
Identification of intrinsic factors leading to long-lived PC
survival could represent therapeutic targets for SLE and other
autoimmune diseases.
Plasma cell survival depends on cytokines secreted by stromal
cells and eosinophils in the BM (136, 137), but they can also
survive in the spleen or other organs, particularly under inflammatory conditions. PCs can survive anywhere as long as sufficient
survival factors are present (138), but niches have the capacity to
support only a limited number of PCs (132). Two related factors
important for survival of PCs are BAFF and APRIL, which act
through binding to TACI and BCMA (139–141). Both cytokines
are anti-apoptotic and increase PC survival (140). A study in
autoimmune thrombocytopenia suggests that an increase in
BAFF caused by B cell depletion promotes differentiation of
short-lived PCs into long lived PCs in the spleen (142, 143). Other
molecules which can enhance survival of PCs are IL-6, VCAM-1,
CXCR4, and CD28 (11, 136, 144).
CD93, a C1q receptor on B cells, is needed for the survival
of PCs in the BM and is expressed only by a subset of PCs in
mice (145). Induction of CD93 expression may, therefore, be an
example of a B cell-intrinsic factor that contributes to PC survival.
Despite the traditional paradigm mentioned above, there
are descriptions of long-lived PCs in T-independent responses,
T cell-deficient, and GC-deficient mice, with survival up to at
least 100 days (12, 132, 146, 147). In addition, PCs exit the GC as
PBs, and require a survival niche for full differentiation. As many
of them fail to find the appropriate niche, not all GC-derived PCs
are long-lived (12). As far as we know now, transcription factors
that drive PC differentiation in each response are similar, and it
is not clear if all PCs have the potential to become long-lived or
whether some are selected, preferentially in the GC, to become
long-lived, and whether this is accompanied by altered expression
of key survival molecules and transcription factors that drive this
distinction.

Tolerance in GC Responses

Although the mechanisms of central tolerance preclude many
autoreactive B cells from entering GCs, self-reactive B cells
developing in the BM can bypass tolerance mechanisms. This
may occur if they are reactive to monovalent antigen, if their
affinity for antigen is below a certain threshold, or if they
are present in an inflammatory milieu (152, 153). Therefore,
it is normal to have circulating autoreactive mature (naive)
B cells (154).
Importantly, however, mechanisms of peripheral tolerance
are also in place to further eliminate autoreactivity. Mature selfreactive B cells can be thwarted from entering the follicle and be
induced to become anergic (155). Still, some self-reactive B cells are
able to enter the follicle. Evidence also suggests that autoreactive
B cells that were initially excluded from the follicle can later be
recruited into the GC, at which point these cells undergo SHM
which may remove autoreactivity (156, 157), but can also lead
to enhanced self-reactivity (153, 158). One important tolerance
mechanism is the short lifespan of these B cells without mitogenic
stimulation. Thus, only in an inflammatory milieu are these cells
likely to access a GC response.
B cells that acquire autoreactivity in the GC must be eliminated or prevented from becoming PCs. In the GC itself, several
tolerance mechanisms have been described, including apoptosis
and receptor editing. However, a recent study showed that autoreactive GC B cells are not strongly selected to undergo apoptosis,
perhaps because so many autoreactive B cells are cross-reactive
with an eliciting antigen (104, 159–163). It is conceivable that
these tolerance mechanisms are initiated by lack of cognate T cell

TOLERANCE
Tolerance in EF Responses

As autoimmunity has been traditionally thought to arise through
the GC, tolerance checkpoints in EF responses have not been
extensively studied. Whereas the fast rate of the EF response is
needed for adequate responses against pathogens, it also limits
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help. As described, T-cell help is needed for positive selection of
B cells into PCs in the GC, and without this help, self-reactive PCs
will not develop (100, 102, 152, 153). Thus, although self-reactive
memory B cells can develop, the requirement for Tfh cells and
FDCs that recognize or present the autoantigen makes it more
difficult for non-cross-reactive autoreactive PCs to develop.
T cells recognizing foreign antigen may be able to stimulate
autoreactive GC B cells, if the BCR crossreacts with the eliciting
antigen or an antigen present in a multimolecular complex with
the eliciting antigen.
As IgG + memory B cells in healthy individuals have a much
higher frequency of self-reactivity than IgG + PCs (164), an
additional tolerance checkpoint must exist that prevents the
differentiation of autoreactive PCs in addition to a tolerance
checkpoint in GC B cells (Figure 3). Interestingly, switched PCs
maintain expression of MHC class II and the antigen presentation machinery required for cognate T cell interactions at least
until they are no longer proliferating, suggesting that this stage
of PC differentiation may represent a T cell-dependent tolerance checkpoint (165). Although this has not been extensively
studied, Th cells are required for the completion of GC-derived
PC differentiation (103), and PCs can undergo cognate T cell
interactions after their migration out of the GC at the T–B border (165). This suggests that a lack of T cell help may prevent the
terminal differentiation of autoreactive PCs or that autoreactive B cells committed to becoming PCs are more susceptible
to apoptosis or receptor editing than B cells committed to a
memory pathway.

addition, most studies discriminating EF responses from GC
responses use acute immunization models, and it is not clear if
all the paradigms that have been proposed for the distinction
between EF and GC responses apply in the chronic immune
activation present in autoimmune conditions. Although EF
PC differentiation in autoimmunity has not been emphasized,
recent studies indicate this pathway may have a specific role
in autoimmunity (125, 166, 167). MRL/lpr mice exhibit EF PC
generation, although they have increased formation of spontaneous GCs as well (166, 168, 169). In humans, recent research
supports that a large proportion of the PCs in some SLE patients
are clonally related to naive cells, suggesting an EF origin (125).
Here, we propose mechanisms which can lead to enhanced EF
responses in SLE (Figure 4).

Expansion of MZ B Cells

Marginal zone B cells are expanded in several lupus-prone mouse
strains. In humans, the characterization of MZ B cells is much
more complicated [reviewed in Ref. (13)], and it is unclear if SLE
patients also have an expansion of this population. However, the
high BAFF levels often present in SLE patients would support
MZ expansion. Mice overexpressing BAFF develop an SLE-like
phenotype that is characterized by a high titer of class-switched
autoantibodies and PCs, in a T cell-independent manner (59).
A preference for autoreactive B cells to differentiate into MZ B cells
compared to FO B cells has been described in mice (170–173),
and MZ B cells can differentiate directly into IgG + PCs in EF
responses (174, 175). Therefore, development of serum autoantibodies in some lupus-prone mice has been attributed to MZ
expansion and activation, although some studies have challenged
this paradigm (176–180).

PC DIFFERENTIATION IN SLE
EF PC Differentiation in SLE

Enhanced TLR Signaling

Because there are no definite markers that discriminate PCs
based on their pathway of differentiation, it is hard to establish the pathway through which they were derived, especially
in humans where access to lymphoid organs is limited. In

Another mechanism by which EF PC responses in SLE may be
altered is through enhanced TLR signaling. MyD88-deficient
MRL/lpr mice develop lower autoantibody titers and are

Figure 3 | Tolerance in mature cell subsets in healthy individuals. B-1 cells are not shown in this figure as their relative autoreactivity compared to the other subsets
is not exactly known. Marginal zone (MZ) B cells are enriched for autoreactive B cell receptors (BCRs) (polyreactive or antinuclear) compared to follicular B cells.
IgG + memory B cells have a lower frequency of autoreactivity compared to naive B cells, suggesting a tolerance checkpoint in the germinal center. The
autoreactivity in IgM plasma cells (PCs) has not been directly reported, but the fact that IgM autoantibodies are commonly found in healthy individuals and have an
anti-inflammatory role, suggests that some autoreactive IgM + PCs are present and more common than autoreactive IgG + PCs. The low frequency of autoreactive
BCRs in IgG + PCs compared to IgG + memory B cells suggests an additional strong tolerance checkpoint that prevents the development of serum IgG
autoantibodies.
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Figure 4 | The extrafollicular (EF) pathway for the generation of autoreactive plasma cells (PCs) in systemic lupus erythematosus. Shown here are the potential
mechanisms that can contribute to enhanced extrafollicular PC responses. These include (1) expansion of marginal zone (MZ) B cells, which often exhibit
autoreactive receptors; (2) increased Toll-like receptor (TLR) signaling, which can directly activate B cells (B cell-intrinsic) or can enhance Th responses through their
effect on dendritic cells (B cell-extrinsic); (3) B cell hyperresponsiveness, which can affect the activation of follicular B cells; (4) increased class switch recombination
which can lead to more pathogenic IgG autoantibodies; (5) somatic hypermutation which can lead to affinity maturation of autoreactive PCs; and (6) increased PC
survival.

protected from disease (181, 182), suggesting a role for TLRs in
EF responses in MRL/lpr mice. Although TLR-7 or -9 deficiency
each diminished the production of specific types of autoantibodies
in MRL/lpr mice, only TLR-7 deficiency diminished lymphocyte
activation, IgG production, and kidney disease (183, 184). This
suggests that although each receptor can enhance EF responses,
only TLR-7 induces the production of pathogenic antibodies,
or permits the inflammatory response needed to cause disease.
Besides a B cell-intrinsic role of TLR signaling, B cell extrinsic
TLR signaling can also enhance T–B interactions through the
increased activation of DCs (185). Enhanced T–B interactions
in this situation have the potential to enhance T-dependent PC
differentiation in both EF and GC pathways. B cells as well as
myeloid cells from SLE patients have increased expression of
TLRs, and SLE patients may have increased proinflammatory
responses to TLR ligands (186), which can contribute to stronger
T-independent and T-dependent EF responses.

genetic risk factors for SLE; discussed below) (189), or through
a synergy between BCR triggering and other signaling pathways,
such as TLR, BAFF, and type I IFN, which can each lower the
threshold for B cell activation through the BCR and contribute to
the activation of B cells (59, 190, 191). Type I IFN is necessary for a
complete response after BCR/TLR7 stimulation, and increments
in type I IFN can overcome tolerance that normally occurs after
repetitive stimulation of TLRs (192). The fact that high affinity
B cells are more prone to expansion at the EF PB stage (75, 76)
suggests that the increased BCR signaling that occurs in SLE may
preferentially stimulate EF responses.

Increased CSR

Increased CSR in EF responses is another feature of SLE that may
contribute to enhanced pathogenicity of EF PCs, in particular if
the balance between protective IgM and pathogenic IgG is altered.
Increased CSR has been described both in lupus-prone mouse
models as well as SLE patients (193). In particular, a special subset
of EF T cells in the MRL/lpr mice has been described to contribute
to the expansion of class switched IgG + EF PCs. These EF T cells
are dependent on Bcl-6, Stat3, and ICOS, and they mediate IgG
CSR through CD40–CD40L interactions and IL-21 (167, 168).
A similar subset of T cells has been described in EF responses in

B Cell Hyperresponsiveness

A well-known feature of SLE is B cell hyperresponsiveness, which
causes increased signaling upon BCR ligation by antigen (187, 188).
The increased signaling can derive from increased activity of
signaling molecules in the BCR pathway (many of which are
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non-autoimmune mice, although there they localized at the T–B
border, and it is not clear if they migrate to EF foci as well (80).
EF Th cells express CXCR4, as opposed to Tfh cells which express
CXCR5 (or both) (194, 195). While the EF Th cell subset is present
in MRL/lpr mice which have a dominant EF phenotype, mice with
a more pronounced GC pathway, such as NZB/W, have a more
mixed T cell phenotype (168). IgG CSR in MRL/lpr mice, as well as
in graft versus host-mediated autoimmunity, is almost completely
dependent on ICOS, as ICOS-deficiency leads to lower expression
of CXCR4, as well as diminished secretion of IL-21 (167, 168).
T-independent factors can also increase EF CSR in SLE. In AM14
rheumatoid factor transgenic MRL/lpr mice, T cells are required
for the spontaneous production of rheumatoid factor, but not when
B cells are exposed to chromatin immune complexes which will
trigger both the BCR and TLR (196).
Increased CSR has been described in circulating PBs of SLE
patients, and at least some of these have low mutation rates, suggestive of an EF origin (125). However, all EF-derived PBs need
not have low mutation rates. Factors that increase CSR in EF PCs
in mice, such as IL-21, are increased in SLE patients (197), and
factors that mediate T-independent CSR, such as TLR signaling
and the myeloid-derived cytokine BAFF, are also increased in
SLE (198). It is therefore conceivable that SLE patients can exhibit
increased CSR in EF responses.

to chromatin immune complexes in a T-independent manner
(166, 168, 196, 199). This SHM potentially leads to affinity maturation (although probably to a lesser extent than in the GC) in
autoreactive EF PCs, but no mechanism has been described for
antigen selection and affinity maturation in EF responses.

Increased SHM

B Cell Hyperresponsiveness

GC Responses in SLE

Germinal center responses are well known to be increased in
lupus-prone mice, and SLE patients have increased numbers of
circulating pre-GC B cells, switched memory B cells and Tfh
cells, suggestive of enhanced GC responses (169, 200, 201). Given
that IgG anti-DNA autoantibodies which are considered to be
pathogenic in SLE show evidence of SHM (202), the production
of autoreactive PCs by SHM of nonautoreactive naive B cells
within the GC has been considered an important contributor to
the development of SLE in both mice (203) and humans (204).
The following mechanisms can contribute to GC-derived autoreactive PCs (Figure 5).

Loss of FO Exclusion

In normal conditions, autoreactive naive B cells undergo anergy
that leads to FO exclusion and prevents their recruitment into GC
responses. However, in SLE, these B cells are able to enter the GC,
and continue their differentiation into PCs (155, 205).

Besides the increased CSR in EF PCs in MRL/lpr mice, SHM has
also been shown to occur in EF foci, probably under the influence of EF Th cells. However, SHM can also occur in response

As discussed above, B cell hyperresponsiveness can enhance
EF responses and may also potentiate GC responses (206).
Hyperresponsiveness could lead to increased positive selection

Figure 5 | The germinal center (GC) pathway for the generation of autoreactive plasma cells (PCs) in systemic lupus erythematosus. Shown here are the potential
mechanisms that can contribute to enhanced PC differentiation during GC responses. These include (1) loss of follicular exclusion, which can lead to recruitment of
autoreactive B cells into GC responses; (2) B cell hyperresponsiveness which can affect the activation of follicular B cells; (3) increased Toll-like receptor (TLR)
signaling, which can affect initial activation of B cells as well as the GC response itself; (4) de novo autoreactivity, generated through somatic hypermutation (SHM)
and leading to the generation of autoreactive GC B cells from non-autoreactive precursors; (5) aberrant selection and survival, which can diminish tolerance
mechanisms; (6) increased T follicular helper (Tfh) activity, which can increase the extent of GC responses as well as PC differentiation; (7) cell fate decisions that
increase PC differentiation; and (8) increased PC survival.
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in the light zone and subsequent proliferation in the dark zone,
thereby amplifying GC responses (207).

differentiation of autoreactive B cells into autoreactive antibody
secreting PCs (219). In lupus-prone mice, OX40L expression by
B cells contributes to the autoimmune phenotype, presumably
through its effect on Tfh cells (90, 220).

Increased TLR Responses

Toll-like receptors, which are involved in the EF pathway, also
have a role in the GC response. Loss of MyD88 causes a loss of
GC formation; interestingly, this alteration may be attributed to
the function of TLR-7 and not TLR-9 (208, 209). Increased function of TLR-7 causes an increment in spontaneous GC formation
and an autoimmunity phenotype (208). B cell-intrinsic MyD88
signaling specifically enhances GC responses when antigen and
TLR ligand are coupled; self-antigen that can trigger both TLRs
and the BCR will presumably have the same ability. It was recently
demonstrated that FDCs, which are crucial for the maintenance
of GCs and FO architecture, express type I IFN through a TLR-7
pathway upon internalizing complement-opsonized self-immune
complexes through the complement receptor CD21 in the 564Igi
RNP-specific lupus mouse model; this pathway is important for
spontaneous GC formation and production of isotype-switched
autoantibodies (210). 564Igi BM chimeras in which the recipient
FDCs were TLR-7-deficient exhibited less autoimmunity. As
many SLE antigens can activate TLRs (1, 190, 191), these represent potent pathways to amplify GC responses.

Increased PC Differentiation

B cell hyperresponsiveness may also increase the generation of
PCs in SLE by directing more B cells to undergo PC differentiation. SLE patients often have increased numbers of circulating
PBs; in one study this inversely correlates with the number of
CD27 + memory cells, suggesting a preferred differentiation
pathway (221). Lupus-prone mice, including the ones that have
a GC phenotype, have vast increases in their PC numbers, which
exceeds the expansion of the memory compartment. This suggests that there may be preferential output of PCs from the GC
in SLE.

Increased Survival of PCs

Another possible mechanism for increased autoantibody titers is
increased survival of PCs (Figures 2 and 3), which might occur
if excess survival factors are present. Increased expression of the
cytokines BAFF, APRIL, and IL-6 is present in lupus-prone mice
(222, 223), suggesting that these cytokines can support enhanced
PC survival. Although in healthy mice a limited number of PCs
can survive in BM and spleen, these organs in lupus-prone mice
gain additional capacity and exhibit an increased number of PCs
(224). Both lupus-prone mice and SLE patients often exhibit
hypergammaglobulinemia (225, 226), which may also be caused
by an increased capacity to support PC survival in SLE patients.
As both EF and GC-derived PCs can either stay in the spleen
or stay in the lymph nodes or migrate to the BM, these factors
will probably affect both types of PCs. In addition, several lupusprone mouse strains have increased levels of CXCL12 in their
inflamed kidneys, which may allow recruitment of PCs to this
organ (226–228).

De Novo Autoreactivity

Although loss of FO exclusion can lead to recruitment of autoreactive naive cells into GC reactions, SHM of nonautoreactive
B cells can lead to de novo autoreactivity in GC B cells (202, 211).
Whether these cells are able to differentiate into PCs has not been
reported, but most pathogenic antibodies in SLE show signs of
SHM, and de novo autoreactivity explains a large fraction of the
autoreactive IgG + memory cells in SLE patients (204, 212). These
studies suggest that GC B cells retain autoreactivity generated
through SHM.

Aberrant Selection and Survival of GC B Cells

GENETIC RISK ALLELES

Another mechanism for the generation of autoreactive PCs in the
GC is increased survival of GC B cells. It has been shown that
SLE patients have increased levels of BAFF (213). While BAFF
has a large role in the EF pathway of differentiation of PCs, it
also expands the Tfh cell population and promotes formation of
GC and survival of B cells. This could be a contributing factor
in allowing the breach of B cell tolerance seen in SLE patients
(214, 215). As a result of increased BAFF, naive B cells with
moderate affinity that would normally undergo apoptosis, may
be rescued and enter a GC response.

Whereas both EF and GC pathways can lead to autoantibody
production, we propose that genetic factors may cause a
dominance of either of these pathways in individual patients.
Approximately one hundred risk loci have been associated
with SLE, and genes within these loci have been broadly cast
into categories involving DNA degradation and clearance of
apoptotic/cellular debris, innate immunity, including TLR and
IFN signaling, and adaptive immunity (229). Some overlap or
fall outside these categories, and others are undefined. Most
variants are in non-coding regions that may alter expression
levels that can determine the magnitude of a response in a celllineage and stage-specific manner. Several risk genes have been
described to alter B cell selection, activation, differentiation
and/or survival in a B cell-intrinsic fashion, including LYN,
BLK, BANK1, PTPN22, TNFAIP3, TNIP1, CSK, and FCGR2B
(189, 230). Although it is known that these risk alleles alter
B cell signaling, their effect on PC differentiation has not been

Increased Tfh Activity

Another mechanism that leads to the development of autoreactive PCs in the GC is increased Tfh activity (216). One cytokine
important for the development of autoreactive PCs is IL-21, a
cytokine produced by Tfh cells (72). The number of Tfh cells as
well as the level of IL-21 has been shown to be increased in lupusprone mice and SLE patients (217, 218). IL-21 increases IgG PC
number (72, 217), and Tfh cells can alter selection and allow the
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Function of gene

Function of risk allele

Potential role in EF

Potential role in GC

HLA class II genes

Antigen presentation

Presentation of self-specific T cell
epitopes

May increase T-dependent
EF responses

Expansion of Tfh, GC responses and
PC differentiation

TNFS4 (OX40L)

Costimulatory molecule on many
cell types primarily interacting with
OX40 on activated T cells promoting
T cell functions, cytokine and Ab
production, and PC generation

Most likely a response eQTL, as DNA
heterozygous for the 5′ rs2205860
SNP had enhanced binding to NF-κB;
no significant differences in basal
expression in EBV-transformed cells
or primary cells

Required for T cell-dependent
EF Ab response driven
by MZ DCs

Supports Tfh maturation in mice
(B cell-intrinsic) and in humans
(expression on myeloid APCs)

(64, 90, 220,
233, 234)

CD80

T cell costimulation through CD28,
CTLA-4, PD-L1

Unknown

Little effect on Ab production
by short-lived plasmablasts
(in CD80−/− mice)

Increased maturation of Tfh and
generation of long-lived PC

(91)

LYN

Src-family kinase that phosphorylates
both activating and inhibitory receptors
in B cells and myeloid cells. Its role in
activating ITAMs is probably redundant
with other Src family kinases, therefore
its role in inhibitory receptors seems
most crucial

Unknown SLE patients have
decreased expression of Lyn
in B cells

Lyn−/− mice have EF PC
differentiation without GCs
in some studies

Lyn−/− mice have spontaneous
GCs in some studies

(187, 235, 236)

BLK

Src-family kinase that phosphorylates
both activating and inhibitory receptors
in B cells

Decreased expression in B cells,
increased B cell activation

Increased TI IgG antibody
responses in Blk+/− mice,
with no effect on IgM

Increased numbers of switched memory
cells in risk carriers suggests more active
GC responses, but TD antibody responses
in Blk+/− or −/− mice not affected

(237–240)

BANK1

Signaling molecule involved in BCRand CD40-mediated signaling in B cells,
positively regulates Ca2+ release in B cells,
negatively regulates CD40-mediated
signaling

Differential expression of two splice
variants, but functional consequences
unknown

Normal antibody responses
to TI antigen, but the IgM
response in TD responses
was increased, possibly due
to increased survival of EF PCs

Normal IgG antibody responses to TD
antigen suggesting that there is no major
influence on switched TD responses,
although there is a slight increase in
spontaneous IgG2a in
Bank1−/− mice

(241–243)

PTPN22 (Lyp)

Protein tyrosine phosphatase that
has inhibitory function in B and T cell
signaling

Risk allele has increased inhibitory
function, causing decreased B cell
activation, proliferation and signaling
leading to impaired central B cell
tolerance as well as impaired T cell
responses

Impaired central tolerance; unclear
if PTPN22 affects EF responses;
deficiency of PEP (mouse ortholog)
in mice did not alter spontaneous
IgM and IgG3 levels, suggesting
no effect on extrafollicular antibody
production

Lower frequency of memory cells in risk allele
carriers suggests that it may inhibit GC
responses consistent with increased GCs
and serum IgG in PEP−/− mice

TNFAIP3 (A20)

Negative regulator of NF-κB signaling
in response to TLR, TNF, and CD40
signaling in B cells and other immune
cells

Reduced expression in EBV
transformed cells with one risk variant
and reduced anti-inflammatory activity
in transfected HEK cells with another
risk variant

B cell-specific A20 deficiency in
mice leads to alterations in the MZ
compartment and consistently
enhanced IgM production
(spontaneous, as well as
TD and TI immunizations),
but no difference in IgG3

B cell specific A20 deficiency in mice leads
to elevated numbers of GC B cells, and
spontaneous IgG2 levels in old mice which
deposited in kidneys; however, inconsistent
effects on TD IgG production upon
immunization in different studies

11

Gene
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(248–253)

Function of risk allele

Potential role in EF

Potential role in GC

Reference

Ubiquitin-binding protein with diverse
targets; interaction with TNFAIP3
negatively regulates NF-κB; also known
to repress PPARs, which may increase
B cell activity

Reduced expression in EBVtransformed B cells from H1 and H2
risk haplotypes; H1 contains coding
SNP near a nuclear export sequence

Mutation of polyubiquitin binding
site increased formation
of EF PCs

Mutation of polyubiquitin-binding site
induced spontaneous GC, increased TFH,
CSR, and production of autoreactive Abs
thru TLR-mediated NF-κB pathway

(254, 255)

CSK

Tyrosine kinase protein that
phosphorylates
Src family kinases leading to their
inactivation. Src family kinases can act on
both activating and inhibitory receptors in
B and T cells

Increased expression in B cells,
increased B cell activation (Lyn
phosphorylation, Ca2+ mobilization),
expansion of transitional B cells

Unknown, but increased signaling
may enhance PC differentiation

Csk is low in memory cells but its function
in GC responses is not known

(256)

FCGR2B

Inhibitory receptor for IgG on B cells
and other immune cells

Impairment of receptor mobility, lipid
rafts and inhibitory signaling

Enhanced antibody production
upon TI immunization, although
not observed in all studies

Enhanced GC responses in FCGR2B−/−
mice. Spontaneous GC B cells have
increased self-reactivity, but the checkpoint
to PCs is still intact in FCGR2B−/− mice, so
uncertain if autoreactive PCs in these mice
are GC-derived

(150, 257–262)

IRF5

Production of type I IFN in response to
TLR ligands, macrophage polarization,
enhanced PC differentiation

Increased expression and activation
in monocytes from SLE patients with
the risk allele

IRF5−/− mice have decreased IgG1
responses upon TI immunization
and have decreased PC numbers
in MRL/lpr mice, suggesting that
increased expression of IRF5 may
enhance EF responses

IRF5−/− mice have diminished GC-derived
antibodies, suggesting the IRF5 risk allele
may enhance GC PC differentiation

(263–267)

STAT4

Transcription factor critical for myeloid
and lymphocyte functions; major
responder to IL-12; role in IFN-α signaling

Increased expression in PBMCs
correlated with SNPs rs3821236,
rs3024866 (both in the same
haplotype block) and rs7574865
but not with other SNPs

STAT4−/− had no effect on
antibody titers or pathology in EF
model (MRL/lpr)

Regulates Tfh through Bcl-6 and T-bet
in T cells; indirectly upregulates T-bet in
B cells, which facilitates spontaneous GC;
STAT4−/− reduced autoantibody production
and glomerulonephritis in B6.TC model
(Sle1,2,3 congenic)

(268–270)

BACH2

Transcriptional repressor that promotes
CSR/SHM and is required for memory
B cell differentiation

No expression differences associated
with rs597325 in primary blood cell
types

Deficiency increases IgM PC
differentiation in vitro

Bach2 can enhance memory B cell
differentiation while blocking plasma cell
differentiation

(105, 271–273)

PRDM1 (Blimp-1)

Transcription factor required for PC
differentiation/transcription factor that
alters DC function

Decreased expression of Blimp-1 in
DCs leading to increased cytokine
production (unknown function of risk
allele in PCs)

Unknown

Expansion of Tfh and increased GC
responses in DC-Blimp-1-deficient mice

(274, 275)

IRF8

Transcription factor that inhibits PC
differentiation together with PU.1 and
distribution into FO or MZ compartments

Increased expression in EBVtransformed cells

Increased IRF8 expression
presumably would decrease
PC differentiation

Increased function of IRF8 could lead to
enhanced GC responses, through regulation
of Bcl-6, AID, and MDM2

(276–278)

IKZF3 (Aiolos)

Transcription factor involved in
lymphocyte development and function;
important in B cell maturation and
activation

Unknown

Deficiency impairs the MZ B cell
compartment but not the generation
of short-lived PCs following
immunization

Deficiency induces spontaneous GCs and
production of autoantibodies; deficiency
prevents generation of high-affinity BM
PCs following immunization

(279–281)
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(290–293)
T-dependent IgG2a/c OVA responses are
decreased in SLC15a4−/− mice, but not in
SLC15a4 mutant mice. IgG autoantibodies
in pristane-induced lupus aC15a4 deficiency,
suggesting that reduced expression in risk
allele carriers may block GC-derived PCs
SLC15a4 mutant mice, which
are unable to produce IFN1, have
reduced anti-chromatin IgG and
IgM in B6/lpr mice, but have
otherwise normal T-dependent and
independent responses
One risk variant is associated with
reduced expression in monocytes
Lysosomal amino-acid transporter
required for endosomal TLR signaling
and IFN1 production
SLC15A4
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extensively investigated, and most of our understanding of the
role of these genes in EF and GC responses derives from mouse
models. Other risk alleles are involved in B–T cell interactions,
memory or PC differentiation, and IFN/TLR signaling. For
many of these, the functional consequence of the risk allele has
not been determined. However, it is reasonable to ask whether
these risk alleles may alter EF or GC responses.
Table 1 shows risk alleles that can alter B cell responses and
subsequently PC differentiation. These risk alleles can function
in a B cell-intrinsic or -extrinsic manner. We propose that some
risk alleles, such as TLR7, FAS, IRF5, TNFAIP3, and TNIP1, can
modify both EF and GC responses.
Certain risk alleles, such as HLA class II genes, FCGR2B,
STAT4, CD80, IRF8, and PRDM1, most likely drive GC
responses, whereas other risk alleles, such as ETS1, LYN, BACH2,
and BLK, may preferentially drive EF responses in SLE, although
this pathway has not been extensively explored. Further
understanding of the exact role of each risk allele in plasma cell
differentiation pathways may enhance our insight into patient
heterogeneity.

CONCLUSION
The categories “potential role in EF or GC” are speculative and based on our understanding of the literature included in the reference column.

(184, 208, 210,
288, 289)
GC responses are driven by B cell-intrinsic
TLR7 in B6 and B6.Sle1b mice and FDCs in
564Igi RNP-specific lupus model
EF PCs in AM14 Tg MRL/lpr mice
are driven by TLR-7
Increased expression in PBMCs
Activation of immune cells by RNA viruses
or self-antigen
TLR7

(286, 287)
Fas/FasL interactions are important for
apoptosis in GC, thereby potentially affecting
survival and selection of autoreactive GC
B cells
Based on studies in MRL/lpr mice,
increased expression of FasL would
be expected to decrease EF PC
responses
Increased surface expression on
circulating fibrocytes
Apoptosis of immune cells through
engagement of Fas
FASL

(282–285)
Loss of anergy may increase participation of
autoreactive B cells in GC reactions
Increased EF PC responses in
Ets1−/−
Reduced expression of Ets1 in EBVtransformed cells and PBMCs
Transcription factor important for
lymphocyte development and
differentiation; it is also involved in
maintaining B cell tolerance through
anergy maintenance
ETS1

Reference
Potential role in GC
Potential role in EF
Function of gene
Gene

TABLE 1 | Continued

PC Differentiation Pathways in SLE

Function of risk allele

Malkiel et al.

In this review, we have described the PC differentiation pathways which can contribute to the development of autoantibody
production in SLE. Whereas both EF and GC pathways may be
active in the same patient, we propose that certain genetic risk
alleles contribute to the dominance of one of these pathways.
The dominant PC differentiation pathway, determined by the
composite of risk alleles, may contribute to patient heterogeneity
and to response to therapy. Although it is likely that different
therapeutics alter each pathway to a different extent, there is
to our knowledge not enough understanding of the molecular
pathways in each response nor is there clear evidence which
therapeutics target which pathway. These pathways are not as
distinct as we thought, nor can the pathway taken by a PC be
easily distinguished with current knowledge. A more thorough
analysis of these pathways, their role in SLE, and the contribution of genetic risk alleles to each pathway may provide us with
distinct targets to allow precision therapy.
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